Goldman Sachs’s Tonix Pharmaceuticals TNXP Stock Holding History

Goldman Sachs’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.26M	Buy	98,356 +45,301	+85%	+$585K	﹤0.01%	5040
2026 Q1	$730K	Buy	53,055 +26,247	+98%	+$404K	﹤0.01%	5325
2025 Q4	$419K	Buy	26,808 +14,086	+111%	+$260K	﹤0.01%	5702
2025 Q3	$307K	Buy	+12,722	New	+$472K	﹤0.01%	5735
2022 Q4	–	Sell	-2	Closed	-$18K	–	6270
2022 Q3	$18K	Buy	2 +1	+100%	+$24.5K	﹤0.01%	5956
2022 Q2	$17K	Hold	1	–	–	﹤0.01%	6202
2022 Q1	$98K	Hold	1	–	–	﹤0.01%	6115
2021 Q4	$219K	Hold	1	–	–	﹤0.01%	5849
2021 Q3	$371K	Buy	+1	New	+$487K	﹤0.01%	5370
2021 Q2	–	Hold	0	–	–	–	6100
2021 Q1	–	Hold	0	–	–	–	5395
2017 Q1	–	Hold	0	–	-$46K	–	7003
2016 Q4	–	Hold	0	–	–	–	6407
2016 Q3	–	Hold	0	–	–	–	6854
2016 Q2	–	Hold	0	–	–	–	6646
2014 Q1	–	Hold	0	–	-$109K	–	6933
2013 Q4	–	Hold	0	–	–	–	6247

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ishara Investments Los Angeles, California $136M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs's TNXP Position: Q2 2026 in Review

Goldman Sachs increased its Tonix Pharmaceuticals (TNXP) stake by 85% in Q2 2026, buying an estimated $585K and bringing the position to 98,356 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #5040.

Goldman Sachs first reported a position in TNXP in Q3 2021 and has held it in 9 quarters since. 103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

Goldman Sachs held 98,356 shares of Tonix Pharmaceuticals worth $1.26M as of Q2 2026.
Goldman Sachs bought 45,301 Tonix Pharmaceuticals shares in Q2 2026, an estimated $585K.
Tonix Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5040 holding.
Goldman Sachs first reported a position in Tonix Pharmaceuticals in Q3 2021 and has held it in 9 quarters since.
103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.